Bliss GVS Pharma gained 1.38% to Rs 212.50 at 10:05 IST on BSE after the company announced that its board of directors will meet on 11 January 2018, for considering disinvestment of subsidiary business.
The announcement was made after market hours yesterday, 4 January 2018.Meanwhile, the S&P BSE Sensex was up 161.65 points or 0.48% at 34,131.29. The S&P BSE Small-Cap index was up 199.65 points or 1.02% at 19,715.29, outperforming the Sensex.
On the BSE, 47,628 shares were traded on the counter so far as against the average daily volumes of 1.08 lakh shares in the past two weeks. The stock had hit a high of Rs 216 and a low of Rs 211.65 so far during the day. The stock had hit a record high of Rs 230 on 2 January 2018. The stock had hit a 52-week low of Rs 129 on 7 June 2017.
The stock had outperformed the market over the past one month till 4 January 2018, gaining 10.4% compared with the Sensex's 3.35% rise. The scrip had also outperformed the market over the past one quarter, rising 32.24% as against the Sensex's 7.26% rise. The scrip had also outperformed the market over the past one year, jumping 31.45% as against the Sensex's 27.55% rise.
The small-cap company has equity capital of Rs 10.31 crore. Face value per share is Re 1.
Bliss GVS Pharma's consolidated net profit surged 88.2% to Rs 39.50 crore on 40.7% growth in net sales to Rs 224.18 crore in Q2 September 2017 over Q2 September 2016.
Bliss GVS Pharma is engaged in developing, manufacturing and marketing pharmaceutical formulations.
Powered by Capital Market - Live News